Cancer treatments should be licensed for all ages, oncologists say
Peer-Reviewed Publication
Updates every hour. Last Updated: 9-Jul-2025 04:11 ET (9-Jul-2025 08:11 GMT/UTC)
Recent results from the NRG-NSABP B-51/RTOG 1304 clinical study showed that the addition of regional nodal irradiation (RNI) does not decrease the rates of invasive breast cancer recurrence in patients whose positive axillary nodes at presentation convert to negative following neoadjuvant chemotherapy. These results were recently published in the New England Journal of Medicine.
Immunotherapy is a revolutionary cancer treatment strategy that leverages the body’s immune system to fight cancer. While immune checkpoint inhibitors significantly improve the therapeutic outcomes in many tumors, most cancer patients cannot benefit from these.
Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control when compared to giving treatments over a longer period, according to breakthrough research led by the Universities of Sheffield and Leeds and Sheffield Teaching Hospitals NHS Foundation Trust.
Tests in 1,225 patients with the most deadly form of skin cancer reveal for the first time a genetic trait among most of those who did not respond to the latest cancer treatments, known as immune checkpoint inhibitors. Metastatic melanoma, as the disease is formally named, kills nearly 10,000 Americans annually.